Matteo Ferrando

Matteo Ferrando

Auto-generated profile, based on publicly available information

Matteo Ferrando

Allergy & Respiratory Diseases, DIMI Dept of Internal Medicine, University of Genoa, IRCCS AOU San Martino-IST, Genoa, Italy

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in International Archives of Allergy and Immunology
Verified
Journal Article
Open access
PDF file
DBDiego Bagnasco
Diego Bagnasco
MFMatteo Ferrando
Matteo Ferrando
Gilda VarricchiGilda Varricchi
Gilda Varricchi
GPGiovanni Passalacqua
Giovanni Passalacqua
Giorgio Walter CanonicaGiorgio Walter Canonica
Giorgio Walter Canonica
Asthma is a high-prevalence disease, still accounting for mortality and high direct and indirect costs. It is now recognized that, despite the implementation of guidelines, a large proportion of cases remain not controlled. Certainly, adherence to therapy and the education of patients remain the primary objective, but the increasingly detailed knowledge about the pathogenic mechanisms and new biotechnologies offer the opportunity to better address and treat the disease. Interleukin (IL)-13 and IL-4 appear as the most suitable targets to treat the T helper 2 (TH2)-mediated forms (endotypes) of asthma. IL-13 and IL-4 partly share the same receptor and signaling pathways and both are deeply involved in immunoglobulin E (IgE) synthesis, eosinophil activation, mucus secretion and airways remodeling. Several anti-IL-13 strategies have been proposed (anrukinzumab, lebrikizunab and tralokinumab), with relevant clinical results reported with lebrikizumab. Such studies facilitate better definition of the possible predictive markers of response to a specific treatment (e.g. eosinophils, total IgE, fraction of exhaled nitric oxide and periostin). In parallel, anti-IL-4 strategies have been attempted (pascolizumab, pitakinra and dupilumab). So far, dupilumab was reported capable of reducing the severity of asthma and the rate of exacerbations. IL-13 and IL-4 are crucial in TH2-mediated inflammation in asthma, but it remains clear that only specific endotypes respond to these treatments. Although the use of anti-IL-14 and anti-IL-13 strategies is promising, the search for appropriate predictive biomarkers is urgently needed to better apply biological treatments.

31 August 2017 in Frontiers in Medicine
Verified
Journal Article
Open access
DBDiego Bagnasco
Diego Bagnasco
MFMatteo Ferrando
Matteo Ferrando
Gilda VarricchiGilda Varricchi
Gilda Varricchi
FPFrancesca Puggioni
Francesca Puggioni
GPGiovanni Passalacqua
Giovanni Passalacqua
Giorgio Walter CanonicaGiorgio Walter Canonica
Giorgio Walter Canonica
The definition of asthma has profoundly changed in recent years, thus recognizing that asthma itself is not a single disease but a heterogeneous disorder that includes different phenotypes and, possibly, endotypes. A more detailed knowledge of the immunological mechanisms of the asthma pathogenesis has enabled identifying interleukin 5 (IL-5) as a crucial cytokine in several asthma phenotypes. IL-5, in fact, exerts selective action on eosinophils which, in turn, sustain airway inflammation and worsen asthma symptoms and control. The development of drugs targeting IL-5 or its receptor alpha subunit (IL-5Rα) has been shown, in clinical trials, a promising different therapeutic approach to a problematic type of asthma, the severe one, whose characteristics make the patient not controlled by normal therapies and , until today, only partially controlled by means of systemic steroid therapy with its well-known side-effects or by Omalizumab in the allergic subtypes. Beginning with the design process of clinical trials, the importance of patient selection was immediately identified, taking into account both medical records, such as exacerbations, lung function and quality of life, and biomarkers like eosinophils that were predictive of therapeutic responses

1 February 2018 in Current Opinion in Allergy and Clinical Immunology
Verified
Journal Article
Closed access
PDF file
Giorgio Walter CanonicaGiorgio Walter Canonica
Giorgio Walter Canonica
MFMatteo Ferrando
Matteo Ferrando
IBIlaria Baiardini
Ilaria Baiardini
Francesca PuggioniFrancesca Puggioni
Francesca Puggioni
FRFrancesca Racca
Francesca Racca
EHEnrico Heffler
Enrico Heffler
Purpose of review: In this review, we herein describe the progress in management of severe asthma, evolving from a ‘blockbuster approach’ to a more personalized approach targeted to the utilization of endotype-driven therapies. Recent findings: Severe asthma characterization in phenotypes and endotypes, by means of specific biomarkers, have led to the dichotomization of the concepts of ‘personalized medicine’ and ‘precision medicine’, which are often used as synonyms, but actually have conceptual differences in meaning. The recent contribute of the omic sciences (i.e. proteomics, transcriptomics, metabolomics, genomics, …) has brought this initially theoretic evolution into a more concrete level. Summary: This step-by-step transition would bring to a better approach to severe asthmatic patients as the personalization of their therapeutic strategy would bring to a better patient selection, a more precise endotype-driven treatment, and hopefully to better results in terms of reduction of exacerbation rates, symptoms, pulmonary function and quality of life.

10 March 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
Gilda VarricchiGilda Varricchi
Gilda Varricchi
Gianenrico SennaGianenrico Senna
Gianenrico Senna
SLStefania Loffredo
Stefania Loffredo
DBDiego Bagnasco
Diego Bagnasco
MFMatteo Ferrando
Matteo Ferrando
Giorgio Walter CanonicaGiorgio Walter Canonica
Giorgio Walter Canonica
Human eosinophils represent approximately 1% of peripheral blood leukocytes. However, these cells have the propensity to leave the blood stream and migrate into inflamed tissues. Eosinophilic inflammation is present in a significant proportion of patients with severe asthma. Asthma is a chronic inflammatory disorder that affects more than 315 million people worldwide, with 10% having severe uncontrolled disease. Although the majority of patients can be efficiently treated, severe asthmatics continue to be uncontrolled and are at risk of exacerbations and even death. Interleukin-5 (IL-5) plays a fundamental role in eosinophil differentiation, maturation, activation and inhibition of apoptosis. Therefore, targeting IL-5 is an appealing approach to the treatment of patients with severe eosinophilic asthma. Reslizumab, a humanized anti-IL-5 monoclonal antibody, binds with high affinity to amino acids 89 - 92 of IL-5 that are critical for binding to IL-5 receptor Alpha (IL-5Ralpha). Two phase III studies have demonstrated that reslizumab administration in adult patients with severe asthma and eosinophilia (Greater than 400 cells/microliter) improved lung function, asthma control and symptoms. Thus, the use of blood eosinophils as a baseline biomarker could help to select patients with severe uncontrolled asthma who are likely to achieve benefits in asthma control with reslizumab. In conclusion, targeted therapy with reslizumab represents one step closer to precision medicine in patients with severe eosinophilic asthma.

1 January 2017 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
PDF file
MFMatteo Ferrando
Matteo Ferrando
DBDiego Bagnasco
Diego Bagnasco
Gilda VarricchiGilda Varricchi
Gilda Varricchi
SBStefano Bernardi
Stefano Bernardi
ABAlice Bragantini
Alice Bragantini
Giorgio Walter CanonicaGiorgio Walter Canonica
Giorgio Walter Canonica
Ferrando M, et al. Allergy Asthma Immunol Res. 2017 Jan;9(1):15-24. https://doi.org/10.4168/aair.2017.9.1.15

17 November 2016 in Therapeutic Advances in Respiratory Disease
Verified
Journal Article
Open access
Gilda VarricchiGilda Varricchi
Gilda Varricchi
DBDiego Bagnasco
Diego Bagnasco
MFMatteo Ferrando
Matteo Ferrando
Francesca PuggioniFrancesca Puggioni
Francesca Puggioni
GPGiovanni Passalacqua
Giovanni Passalacqua
Giorgio Walter CanonicaGiorgio Walter Canonica
Giorgio Walter Canonica
Eosinophils represent approximately 1% of peripheral blood leukocytes in normal donors and their maturation and differentiation in the bone marrow are mainly regulated by interleukin (IL)-5 [Broughton et al. 2015]. IL-5, a cytokine that belongs to the β common-chain family, together with IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF), stimulates also the activation and survival of eosinophils and, to some extent, of basophils. IL-5 binds to a heterodimer receptor composed of the specific subunit IL-5Rα and a common subunit βc shared with IL-3 and GM-CSF. Human eosinophils express approximately a three-fold higher level of IL-5Rα compared with basophils. Major sources of IL-5 are T-helper 2 (Th2) cells, mast cells, CD34+ progenitor cells, invariant natural killer (NK) T-cells, group 2 innate lymphoid cells (ILC2s), and eosinophils themselves. ILC2s control not only eosinophil number but also their circadian cycling through the production of IL-5.